Erasca Faces Class Action Over Alleged Misleading Oncology Data

The legal action, filed by Levi & Korsinsky, LLP, covers shareholders who purchased Erasca securities between January 14, 2025, and April 26, 2026. According to the complaint, Erasca built its investment thesis on repeated, favorable comparisons to Revolution Medicines’ RMC-6236. The lawsuit alleges these head-to-head claims were deceptive, exposing the company to potential patent infringement and trade secret misappropriation charges that were never disclosed to the market.

Evidence of these risks surfaced following a sharp correction in the company's share price, which dropped from $21.49 to $9.90. Plaintiffs contend that Erasca’s management intentionally inflated the stock value to facilitate a $258.8 million common stock offering in January 2026. Beyond the benchmarking controversy, the complaint highlights allegations that the company omitted a Grade 5 treatment-related adverse event from its initial Phase 1 safety data. Investors seeking to serve as lead plaintiff must file their applications by August 10, 2026.